查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138319

脂質體阿黴素的全球市場-2022-2029

Global Liposomal Doxorubicin Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球脂質體阿黴素市場的增長是由全球癌症發病率上升和製造阿黴素的公司數量不斷增加推動的。

全球癌症發病率上升，生產阿黴素的公司越來越多

預計越來越多的公司生產阿黴素將推動市場增長。

癌症患者數量的增加正在推動脂質體阿黴素的全球市場。例如，根據世界衛生組織 (WHO) 的數據，癌症每年佔全球死亡人數的 13%。此外，預計未來幾十年癌症發病率將增加 70%，預計 2015 年至 2022 年期間，世界老年人口將增加近一倍，從 12% 增加到 22%。事實已經如此。從 2015 年到 2030 年，全球各類癌症的發病率預計將以 2.5% 的複合年增長率增長。預計癌症死亡率的增長速度將高於發病率，2015-2030 年的複合年增長率為 2.6%。

製造商增加產品開發和新參與者進入市場也有望在預測期內推動市場增長。例如，2019 年 3 月，Cytori Therapeutics, Inc. 向歐洲醫療機構（EMA）提交了鹽酸阿黴素 Cytori 的正式上市前申請。該申請是 EMA 集中審批流程下第 58 條申請上市許可申請 (MAA) 的前身。

與阿黴素相關的副作用預計會阻礙市場增長。

與脂質體阿黴素相關的一些副作用預計會在預測期內阻礙市場增長。一些副作用包括感染風險增加、氣短或膚色蒼白、瘀傷、牙齦出血、流鼻血、疲倦或虛弱（疲勞）在治療期間或治療後、手腳疼痛、發紅、皮膚。脫皮、厭食和體重減輕、腹瀉和便秘。

行業分析

全球脂質體阿黴素市場根據波特五力分析、流行病學、監管分析、供應鏈分析、產品創新和未滿足的需求等各種行業因素對市場進行深入分析。

全球脂質體阿黴素市場報告將提供對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 全球癌症發病率上升，阿黴素製造商數量增加
    • 限制因素
      • 與阿黴素相關的副作用
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 流行病學
  • 監管分析
  • 供應鏈分析
  • 產品創新
  • 未滿足的需求

第 6 章按產品分類

  • Doxyl/Cailex
  • Lipodox
  • 米奧塞特
  • 其他

第 7 章按配方

  • 凍乾粉
  • 阿黴素注射液

第 8 章按應用程序

  • 卡波西肉瘤
  • 白血病
  • 乳腺癌
  • 卵巢癌
  • 多發性骨髓瘤
  • 子宮內膜癌
  • 肝癌
  • 骨肉瘤
  • 腎癌
  • 其他

第 9 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • Pfizer Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • SRS Pharmaceuticals Pvt. Ltd.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Cadila Pharmaceuticals
  • Merck & Co.
  • Cipla, Inc.

第13章 脂質體阿黴素世界市場-DataM

簡介目錄
Product Code: DMPH2194

Market Overview

Liposomal doxorubicin Market size was valued US$ 1,160 million in 2022 and is estimated to reach US$ 2 billion by 2029, growing at a CAGR of 6.2 % during the forecast period (2022-2029).

Liposomal Doxorubicin is a chemotherapy drug-containing doxorubicin (Adriamycin) wrapped up in a fatty covering called a liposome. Doxorubicin blocks an enzyme called topoisomerase 2 that cancer cells need to divide and grow. Liposomal doxorubicin is doxorubicin contained in tiny spheres called pegylated liposomes. These spheres keep the doxorubicin in the bloodstream longer so that more of the drug reaches the cancer cells. It is used to treat several types of cancer, including breast cancer, ovarian cancer, Kaposi's sarcoma, and multiple myeloma.

Market Dynamics

The global liposomal doxorubicin market growth is driven by the surge in prevalence of cancer globally and Increasing number of companies manufacturing doxorubicin.

The rising prevalence of cancer globally and Increasing number of companies

manufacturing doxorubicin are expected to drive market growth.

The rising number of cancer cases drives the global liposomal doxorubicin market. For instance, according to the World Health Organization (WHO), cancer accounts for 13% of deaths globally every year. Moreover, a 70% increase in cancer incidences is anticipated over the next couple of decades, and the global geriatric population is anticipated to nearly double from 12% to 22%, from 2015 to 2022. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. The mortality rate of cancers is likely to increase at a higher rate than the incidence rate during 2015-2030, at a CAGR of 2.6%.

The market growth is also estimated to boost over the forecast period due to rising product development by manufacturers and new players entering the market. For instance, in March 2019, Cytori Therapeutics, Inc. has filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the precursor to filing an Article 58 Application for a Marketing Authorization Application (MAA) via EMA's centralized approval procedure.

Side Effects associated with doxorubicin is expected to hamper the market growth.

There are some side-effects associated with liposomal doxorubicin which are expected to hamper the market's growth over the forecast period. some of the side-effects include increased risk of getting an infection, breathlessness and looking pale, bruising, bleeding gums and nosebleeds, tiredness and weakness (fatigue) during and after treatment, soreness, redness and peeling of your hands and feet, loss of appetite and weight loss, diarrhea or constipation, among others.

Industry Analysis

The global liposomal doxorubicin market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces Analysis, Epidemiology, Regulatory Analysis, Supply Chain Analysis, Product Innovations, Unmet Needs.

Segment Analysis

Doxil/Caelyx segment is expected to hold the largest market share in global liposomal doxorubicin market

The market is segmented into Doxil/Caelyx, Lipodox, Myocet, and Others based on product type. Doxil/Caelyx segment accounted for the highest market share, owing to the rising incidence of ovarian and breast cancers. The increasing demand for Doxil or Caelyx (J&J) as a second-line treatment for ovarian carcinoma is also expected to boost its growth over the forecast period. Caelyx/Doxil is a novel pegylated liposomal formulation of the first-generation anthracycline, doxorubicin. The pharmacokinetics of this polyethylene-glycol-coated liposome is characterized by a reduced volume of distribution, a long intravascular circulating half-life and slow plasma clearance compared with free doxorubicin.

By application, the liposomal doxorubicin market is segmented into Kaposi sarcoma, leukemia, breast cancer, multiple myeloma, ovarian cancer, endometrial cancer, liver cancer, bone sarcoma, kidney cancer, and others. Among these, breast cancer accounted for the highest market share in 2018, owing to rising demand for the treatment in increasing breast cancer cases globally. According to Breastcancer.org, about 1 in 8 U.S. women (about 12%) develop invasive breast cancer over the course of their lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 62,930 new non-invasive (in situ) breast cancer cases. About 2,670 new cases of invasive breast cancer are expected to be diagnosed in men in 2019. A man's lifetime risk of breast cancer is about 1 in 883. According to the American Cancer Institute, Doxorubicin is used during advanced breast cancer treatment as a chemo drug. It is observed that 3 million women diagnosed with breast cancer are currently there in the United States. Hence, an increasing burden of breast cancer leads to a rise in demand for treatment.

Geographical Analysis

North America region holds the largest market share in the global liposomal doxorubicin market

North America is dominating the global liposomal doxorubicin market, accounting for the largest market share in 2018, owing to an increasing number of cancer cases and consequently growing demand for doxorubicin in mono and combination chemotherapies. United States is the biggest market share holder of liposomal doxorubicin development and it has been allowed to import the medicine under the exercise enforcement discretion. The huge demand of liposomal doxorubicin in the market is fueling the doxorubicin HCl liposome injections import. As of January 2019, more than 3.1 million women have a history of breast cancer in the U.S. Also, the growing number of partnerships, mergers and acquisitions for clinical trials with technologically advanced doxorubicin formulations drive the market's growth in this region.

Competitive Landscape

The liposomal doxorubicin market is highly competitive with the presence of a large number of major players. Some of the major players in the global liposomal doxorubicin market include Johnson & Johnson, SRS Pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Cadila Pharmaceuticals, Merck & Co., Cipla, Inc., Pfizer Inc., among others.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the liposomal doxorubicin market globally. For instance,

In January 2019, Celsion Corporation, an oncology drug development company, announced results from Phase I TARDOX trial of ThermoDox conducted at the University of Oxford, United Kingdom. The TARBOX trial evaluated the safety and efficacy of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, along with focused ultrasound for the treatment of liver cancer.

Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. is an American multinational pharmaceutical corporation that works in biotechnology domain also. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, immunology.

Products Portfolio: NYVEPRIA: It is helpful in reducing the incidence of infection, caused by febrile neutropenia, to the patients that have non-myeloid malignancies and are getting myelosuppressive anti-cancer drugs related with a clinically notable increase of febrile neutropenia.

Key Developments: In Aug 2021, Trillium Therapeutics Inc was attained for around $2.3 billion by this company along with its immuno oncology portfolio.

The global liposomal doxorubicin market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising prevalence of cancer globally and Increasing number of companies manufacturing doxorubicin
    • 4.1.2. Restraints:
      • 4.1.2.1. Side Effects associated with Doxorubicin
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Epidemiology
  • 5.3 Regulatory Analysis
  • 5.4 Supply Chain Analysis
  • 5.5 Product Innovations
  • 5.6 Unmet Needs

6. By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product Segment
  • 6.2. Doxil/Caelyx
      • 6.2.1.1. Introduction
      • 6.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Lipodox
  • 6.4. Myocet
  • 6.5. Others

7. By Drug Formulation

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 7.1.2. Market Attractiveness Index, By Drug Formulation Segment
  • 7.2. Lyophilized Powder
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Doxorubicin Injection

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Kaposi Sarcoma
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Leukemia
  • 8.4. Breast Cancer
  • 8.5. Ovarian cancer
  • 8.6. Multiple Myeloma
  • 8.7. Endometrial Cancer
  • 8.8. Liver Cancer
  • 8.9. Bone Sarcoma
  • 8.10. Kidney Cancer
  • 8.11. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Formulation
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1 Pfizer Inc.
    • 12.1.1 Company Overview
    • 12.1.2 Product Portfolio and Description
    • 12.1.3 Key Highlights
    • 12.1.4 Financial Overview
  • 12.2 SRS Pharmaceuticals Pvt. Ltd.
  • 12.3 Johnson & Johnson
  • 12.4 Sun Pharmaceutical Industries Ltd.
  • 12.5 Cadila Pharmaceuticals
  • 12.6 Merck & Co.
  • 12.7 Cipla, Inc.

LIST NOT EXHAUSTIVE

13. Global Liposomal Doxorubicin Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Distribution Channel
  • 13.3. Contact Us